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Objective - To assess the effects of weight reduction
with 10mg of sibutramine or placebo on blood pressure
during 24 hours (ambulatory blood pressure monitoring),
on left ventricular mass, and on antihypertensive therapy
in 86 obese and hypertensive patients for 6 months.
Methods - The patients underwent echocardiogra-
phy, ambulatory blood pressure monitoring, and measure-
ment of the levels of hepatic enzymes prior to and after
treatment with sibutramine or placebo.
Results - The group using sibutramine had a greater
weight loss than that using placebo (6.7% versus 2.5%;
p<0.001), an increase in heart rate (78.3±7.3 to 82±7.9
bpm; p=0.02), and a reduction in the left ventricular mass/
height index (105±29.3 versus 96.6±28.58 g/m; p=0.002).
Both groups showed similar increases in the levels of
alkaline phosphatase and comparable adjustments in an-
tihypertensive therapy; blood pressure, however, did not
change.
Conclusion - The use of sibutramine caused weight
loss and a reduction in left ventricular mass in obese and
hypertensive patients with no interference with blood
pressure or with antihypertensive therapy.
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The prevalence of obesity and its associated morbidi-
ties has increased in several countries worldwide, including
Brazil 1,2. The increase in body mass index has proved to be
a determinant factor for elevation of blood pressure, both
for obese and nonobese children and adults 3,4. In addition,
the presence of obesity is related to a 2.5 higher risk of arte-
rial hypertension, mainly in patients with central body fat
distribution 5. Several hypotheses exist for the pathophy-
siology of arterial hypertension in this obese population.
The first and more accepted hypothesis proposes that hy-
perinsulinemia secondary to insulin resistance existing in
these patients leads to greater sympathetic activity and to
renal sodium retention, which would account for the increa-
se in pressure levels 6-8. The second hypothesis associates
the arterial hypertension existing in these patients with the
mechanical compression of renal parenchyma by visceral
fat. This leads to hyperactivation of the renin-angiotensin-
aldosterone system (RAAS), higher sodium reabsorption,
and a subsequent elevation in blood pressure by a mecha-
nism independent from insulinemia 9,10.
Even though we have not reached a consensus about
the causes of arterial hypertension in the obese, several
clinical studies confirm the importance of weight loss to
better control blood pressure levels 11,12.
The great challenge has been to find effective clinical
treatments, which do not impair blood pressure control, to
induce weight loss in hypertensive patients. Of the several
treatments available for weight control, we can count on ap-
petite suppressing drugs, which comprise a generic class of
drugs derived from amphetamines that act through adrener-
gic receptors, and, therefore, may aggravate hypertension.
More recently, other options include orlistat that inhibits
gastrointestinal fat absorption, and sibutramine, an appe-
tite suppressant that blocks serotonin, dopamine, and nora-
drenaline reuptake 13.
 The use of sibutramine is associated with an increase
in satiety scores and a lack of decline in 24-hour energy
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expenditure 14,15, which make sibutramine efficient in indu-
cing weight loss. Several studies show an adequate tolera-
bility profile for the drug; however, aspects referring to
hypertensive patients are still inconclusive, and the pre-
sence of higher adrenergic activity may interfere with the
benefits resulting from weight loss.
We carried out a prospective, double blind study for 6
months to assess the effects of the use of sibutramine or
placebo on blood pressure levels, left ventricular mass and
evolution of the antihypertensive therapy in obese and hy-
pertensive patients. In addition, we assessed drug tolerabi-
lity through the analysis of the frequency of clinical and
laboratory adverse effects.
Methods
We selected 109 obese patients (30 kg/m2 < BMI
<50kg/m2) who were being followed up at the UNIFESP in
the outpatient clinic for obesity. These patients had arterial
hypertension (95mmHg <DBP <110mmHg; or DBP <95mm
Hg  if on medication) and a preferentially central body fat
distribution (waist/hip ratio above 0.85 for females and 0.95
for males). The following patients were excluded from the
study: diabetic patients undergoing any treatment for wei-
ght loss; patients using medications, such as corticoste-
roids or tricyclic derivatives; and patients with endocrine
diseases that could interfere with body weight. After rando-
mization, the patients were advised to follow a diet of 1,200
and 1,500 calories (females and males, respectively) and re-
ceived placebo or 10mg of sibutramine for 6 months. These
patients were followed up with monthly visits for a complete
physical examination (weight, height, blood pressure, heart
rate, waist and hip circumferences), assessment of adverse
effects, and necessary adjustments in the concomitant anti-
hypertensive medication. During the study, the following
patients were excluded: patients with changes in the hepatic
enzymes above twice the normal limit; patients whose di-
astolic blood pressure levels exceeded 110mmHg, even un-
der treatment; patients who started to use corticosteroids,
or who interrupted the prescribed medication for more than
1 week. Blood samples were withdrawn at the 1 st, 12th, and
24th weeks to measure alkaline phosphatase (AKP), gamma-
glutamyl transpeptidase (GGT), and glutamic-oxaloacetic
(GOT) and glutamic-pyruvic (GPT) transaminases (method:
spectrophotometry). At the beginning of the study, the pa-
tients underwent the following tests: total cholesterol,
HDL-cholesterol, and triglycerides (method: colorimetric
enzymatic), and the oral glucose tolerance test, with glucose
measurements (method: oxidase glucose) during fasting
and every 30 minutes up to 2 hours after glucose overload.
At the beginning and at the end of the study, the cardiac
mass was measured by Doppler echocardiography (Escote
Biomédica; Florence, Italy), and mass index was calculated
considering the patient’s height, according to Levy and
Lauer et al 16-18, and was used to characterize ventricular hy-
pertrophy in this obese population. A 24-hour blood pres-
sure profile was obtained using 24-hour ambulatory blood
pressure monitoring (Spacelabs 90202 Equipment, Red-
mond, WA). The percentage drop (%D) in mean systolic
blood pressure (MSBP) during sleep was calculated using
the formula: DN = MSBP (wakefulness) - MSBP (sleep) x
100/MSBP (wakefulness).
Statistical analysis: we used the Sigma Stat software
(SPSS Industry). Data were expressed as mean ± standard
deviation. The Student t test for dependent and independent
variables was used for intra- and intergroup comparison,
respectively. The frequencies of adverse effects, causes of
exclusion from the study, and changes in the antihypertensive
medication between the groups were compared using the chi-
square test. It was considered significant a p value < 0.05.
Results
Twenty-three patients (13/10, placebo/sibutramine)
did not complete the study due to different causes: bioche-
mical alterations in the blood (1/1; ns), poor treatment
compliance (8/7; ns), hypertensive crisis due to interruption
of the antihypertensive treatment (1/1; ns); inappropriate
use of corticosteroids (2/1; ns); and pyelonephritis (1/0;
ns). At the end of the study, we assessed 43 patients in each
group, accounting for 88% and 83% of female patients in
the placebo and sibutramine groups, respectively. Except
for age (50.6±8.1 in the placebo group versus 46.4±8.2 in the
sibutramine group, p<0.01), no significant difference was
observed in the initial clinical characteristics between the 2
groups (tab. I). The prevalence of glucose intolerance, total
cholesterol >200mg/dL, and triglycerides >180mg/dL in the
study population was, respectively, 34%, 52%, and 29%.
Considering only the patients who completed the stu-
dy, a weight loss of 6.8±2.3kg (6.7 %) in the sibutramine group
and of 2.4±4.2kg (2.5%) in the placebo group (p<0.001) oc-
curred. Weight loss greater than 5% occurred in 27 (62.8%)
and 10 (23.2%) patients of the sibutramine and placebo grou-
ps, respectively (p<0.001). Table I shows that a significant re-
duction in the waist/hip ratio occurred in the sibutramine
group, indicating an improvement in body fat distribution.
Systolic and diastolic blood pressure measured at the
medical office, the mean systolic (MSBP) and diastolic
(MDBP) blood pressures during ambulatory blood pressu-
re monitoring, the percentage drop (%D) in mean systolic
blood pressure during sleep, and mean heart rate during 24
hours did not significantly change in either group (tab. I).
Heart rate measured at the office showed a significant in-
crease in the sibutramine group (78.3±7.3 versus 82±7.9
bpm; p=0.02), but not in the placebo group (76.3±9.6 versus
75.68±8.8 bpm; ns).
The characteristics of the initial antihypertensive
treatment and its changes throughout the study are detailed
in table II. As can be seen, the proportion of untreated pa-
tients and those treated with 1 or more agents did not differ
in the 2 groups. The proportions of patients using different
classes of antihypertensive agents also did not differ in the
2 groups. Only 18.6% of the patients in both groups were
not using antihypertensive medication at the beginning of
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number or dosage of the antihypertensive agents initially
used. Maintenance of the medication was observed in
39.5% and 53.5% of the patients (p=0.29) in the placebo and
sibutramine groups, respectively, while 32.5% and 30.2% of
the patients, respectively, required an increase in the num-
ber or dosage of the antihypertensive agents used (p=1.0).
Considering the patients in the 2 groups undergoing
echocardiography, the prevalence of ventricular hypertrophy
(LVM/HEI >110g/m) was 31/80 (38.7%) at the beginning of the
study, and 26/81 (32%) at the end of the study (p=0.36; ns).
Left ventricular mass and left ventricular mass index corrected
for height showed a significant reduction after treatment in
the sibutramine group (p=0.002), but not in the placebo
group (tab. I and fig. 1). In the sibutramine group, a tendency
towards correlation between the percentage of weight loss
and the reduction in left ventricular mass index was observed
(r=0.27; p=0.08). Considering only those patients who
achieved weight loss above 5% and underwent the same
analysis, a significant reduction in left ventricular mass index
corrected for height was observed in the sibutramine group
(106.9±31.8 versus 99.8±29.7 g/m; p=0.04). The prevalence of
hypertrophy did not change in the 2 groups.
The most frequent adverse effects were as follows: dry
mouth, insomnia, nervousness, cephalea, constipation,
and arthralgia. None of these adverse effects required
interruption of the medication. Only dry mouth (37.2%
versus 9.3%; p<0.005) and arthralgia (16.2 % versus 2.3%;
p=0.03) were more frequent in the sibutramine group.
Biochemical alterations in alkaline phosphatase (values
>200 IU/L) caused the exclusion of 1 patient in each group.
Biochemical fluctuations below that level were followed up,
and the frequency of values above 100 IU/L prior to and after
the treatment was compared in both groups. Even though the
frequency of alkaline phosphatase values above 100 IU/L
was significantly higher at the end of the study in the
sibutramine group (44.2% versus 18.6%; p=0.02), the mean
values of alkaline phosphatase in these patients did not differ
in the 2 groups (137.3±29.5 versus 147.0±57.7, sibutramine
and placebo groups, respectively; p=0.5). In addition,
considering all patients who completed the study, statistically
significant increases of similar magnitude in alkaline
phosphatase values occurred in the 2 groups (tab. I).
Table I – Clinical and laboratory characteristics, ambulatory blood pressure
monitoring values, and initial and final echocardiographic findings of the
placebo and sibutramine groups (mean±SD))
Placebo (n=43) Sibutramine (n=43)
Physical
examination Basal Final Basal Final
BMI (kg/m2) 38.8±5.4 37.7±5.5 40.1±5.5 37.5±5.6*
WHR 0.97±0.08 0.96±0.08 0.97±0.09 0.94±0.07*
SBP (mm Hg) 149.5±15.0 148.9±21.7 150.2±18.15 145.6±15.1
DBP (mm Hg) 94.16±11.52 92.1±13.5 91.0±12.3 92±13.3
HR (bpm) 76.3±9.6 75.68±8.8 78.3±7.3 82±7.9*
Biochemistry
FA (U/l) 81.4±29.6 99.4±47.1* 83.9±28.7 104.2±38.5*
GGT (U/l) 23.9±15.8 25.2±16.1 26.2±12.8 30.7±21.4
TGO (U/l) 21.5±9.0 21.4±10.4 20.2±5.7 21.3±12.9
TGP (U/l) 23.3±14.8 22.2±13.8 24.3±12.4 24.1±16.7
Ambulatory blood pressure monitoring
day MSBP
(mmHg) 131.4±13.5 130.6±14.9 137.6±14.5 135.7±11.1
day MDBP
(mmHg)  82.9±9.7 81.2±9.3 84.6±9.08 84±8.16
nocturnal MSBP
(mmHg) 120.8±12.6 123±15.5 124.5±16.2 127.43±13.1
nocturnal MDBP
(mmHg) 71.7±9.5 72.4±9.2  71.4±9.7 74.84±9.38
%D (%) 7.9±5.5 7.44±5.2   9.3±7.8 7.9±6.05
24h-HC (bpm) 97.2±9.9 97.8±10.8 100.1±10.05 101.9±8.4
ECO
LVM (g) 176±38.2 164.8±45.0 168.5±51.4 154.6±50.8*
LVM/HEI (g/m) 110.1±22.4 103.9±27.9 105±29.3 96.6±28.6*
*p<0.05 versus basal; BMI- body mass index; WHR- waist/hip ratio; SBP-
systolic blood pressure; DBP- diastolic blood pressure; HR- heart rate; AKP-
alkaline phosphatase; GGT- gamma-glutamyl transpeptidase; GOT- glutamic-
oxaloacetic transaminase; GPT- glutamic-pyruvic transaminase; MSBP- mean
systolic blood pressure; MDBP- mean diastolic blood pressure; %D- percenta-
ge drop in systolic blood pressure during sleep; 24h-HR- heart rate in 24 hours;
LVM- left ventricular mass; LVM/HEI- left ventricular mass corrected to height.
Table II - Characteristics of the antihypertensive treatment in each
group. Number of agents, qualitative distribution of the antihyperten-
sive  drugs in the 2 groups, and evolution of the treatment after 6 months
(placebo and sibutramine)
Placebo Sibutramine
(n=43) (n=43)
Initial number of antihypertensive agents (n) (%)
     None   8 (18.6%)   8 (18.6%) NS
     1 agent 11 (25.6%) 22 (51.1%) NS
     2 agents 16 (37.2%) 10 (23.2%) NS
     3 or more agents   8 (18.6%)   3 (6.9%) NS
Classes of the initial antihypertensive agents (n) (%)
     Diuretics 26 ( 60.5%) 22  (51.1 %) NS
     Beta-blockers   7  (16.2 %)   6  (13.9 %) NS
     ACE inhibitors 18  (41.8 %) 13  (30.2 %) NS
     Calcium blockers   9  (20.9 %)   6 (13.9 %) NS
     Others   3  (6.9 %)   5 (11.6 %) NS
Variation in the medication (n) (%)
     Reduction 12 (27.9%)   7 (16.2%) p = 0.28 (NS)
     Maintenance 17 (39.5 %) 23 (53.5%) p = 0.29 (NS)
     Increase 14 (32.5%) 13 (30.2%) p = 1.00 (NS)
ACE- angiotensin-converting enzyme.
the study. After 6 months of treatment, 27.9% and 16.2% of
the patients (p=0.28) in the placebo and sibutramine
groups, respectively, had evolved with a reduction in the Fig. 1 – Initial and final MVE/ALT in the 2 groups (sibutramine and placebo) mean ± SD.
sibutramine
initial
p=0.002
p=0.002
initiali itial final final
placebo
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Discussion
In our trial, the treatment of obese hypertensive pa-
tients with sibutramine was more effective in inducing
weight loss than that with placebo. In a 6-month period, this
weight loss reached 6.7% in the sibutramine group and
2.5% in the placebo group, which is a value similar to those
obtained in other studies 19,20.
Part of the effects of sibutramine is due to the inhibition
of noradrenaline reuptake with the resulting maintenance of
adrenergic tonus in these patients, which can be beneficial
for avoiding the drop in energy expenditure that follows
weight loss according to the studies by Hansen et al 14 and
Seagle et al 15. This effect, however, could result in an eleva-
tion in blood pressure and a reduction in the antihyper-
tensive benefits of weight loss. In fact, previous studies in
normotensive patients reported elevations in heart rate and
blood pressure associated with the use of sibutramine 15.
In our study, even though an increase in heart rate
measured at the medical office was observed in the sibutra-
mine group, the same was not observed on ambulatory
blood pressure monitoring. No alteration in blood pressure
levels occurred, either at the medical office or on ambulatory
blood pressure monitoring. Concomitant adjustments of the
antihypertensive medication were performed aiming at
avoiding fluctuations in blood pressure. We observed that
increases in the dosage or number of antihypertensive dru-
gs were performed in the same proportion in both groups,
suggesting that the increase in the sympathetic activity is
not of a magnitude sufficient to interfere with blood
pressure control in treated hypertensive patients. On the
other hand, as the weight loss was significantly greater in
the sibutramine group, and the magnitude of the reduction
in the antihypertensive therapy was similar in both groups,
loss of the antihypertensive benefits due to weight loss was
observed.
In the obese population studied, the diuretic, used alo-
ne or in combination, was the most frequently used drug to
treat hypertension followed by angiotensin-converting en-
zyme inhibitors as shown in table II. Due to the constant volu-
me overload that exists in hypertensive obese patients 12, the
association of diuretic drugs is frequently necessary for
adequate blood pressure control.
Even though no reduction in the prevalence of myo-
cardial hypertrophy was observed in the period studied, a
significant reduction occurred in ventricular mass and in its
index corrected for height in the sibutramine group, but not
in the placebo group. This occurred despite the lack of
variations in the different parameters of ambulatory blood
pressure monitoring in the 2 groups, revealing the cardio-
vascular benefits of weight loss not related to blood pres-
sure levels. Myocardial hypertrophy in the obese hyper-
tensive patient is known to result from the 2 following
pathophysiological factors: volume overload determined
by weight and the increase in peripheral vascular resis-
tance. Therefore, after adjustments for height, obese nor-
motensive patients show ventricular hypertrophy of a mag-
nitude similar to that seen in nonobese hypertensive
patients, while obese hypertensive patients show a higher
degree of hypertrophy as compared with that of the other
groups 21. Our results suggest that the reduction in
ventricular mass occurred preferentially due to a reduction
in volume overload secondary to weight loss, because the
blood pressure levels remained stable. Therefore, weight
loss per se, even not associated with a drop in blood
pressure, was related to a cardiovascular benefit in this
group of patients.
An increase in the levels of alkaline phosphatase, but
not in the other hepatic enzymes, was observed in our
patients during the study. At the end of the treatment, the 2
groups showed statistically significant increases in alkaline
phosphatase, but only the sibutramine group experienced
an increased frequency in values above 100 IU/L. Studies
assessing degree 3 obese patients (BMI >40kg/m2) with
hepatic steatosis showed that weight loss, despite its
association with a reduction in hepatic steatosis, may have
resulted in a moderate hepatic inflammatory lesion. This
lesion could be caused by the rapid mobilization of fatty
acids and cytokines in the adipose tissue, especially in
visceral adipose tissue 22,23.
In conclusion, sibutramine proved to be efficient in
inducing weight loss, leading to a reduction in left ventri-
cular mass in obese and hypertensive patients. No signi-
ficant interference was observed in blood pressure levels,
allowing us to state that in obese and hypertensive pa-
tients, in whom clinical supervision and adjustments in the
antihypertensive therapy are possible, the use of sibutra-
mine poses no additional risks. The most frequent adverse
effects associated with the use of sibutramine in this popu-
lation were dry mouth and arthralgia, and a higher frequency
of insomnia or irritability, as suggested in other studies, was
not found. The alterations reported in alkaline phosphatase
cannot be attributed to the use of sibutramine and may be
associated with the mobilization of visceral adipose tissue;
larger studies, however, are required to confirm this
hypothesis.
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